ClinicalTrials.gg
RecruitingNCT07178951Updated Nov 9, 2026

Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis

An interventional study of Neurotomy of the medial sensory articular branches in Osteoarthritis (OA) of the Knee, Knee Pain Arthritis and Chronic Knee Pain, sponsored by FUSMobile Inc.. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by FUSMobile Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.

Planned enrollment
165th of 176
10 · median 98
Started
2026
with 6 others
No phase
101 of 205
16 open now
Primary completion
2026-12
later than 13 of 45 live
Registered
197th of 205
by date

Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 165th largest by planned enrollment of the 176 interventional ones that give a count, is one of 7 that started in 2026, is one of 101 with no phase, reaches primary completion later than 13 of the 45 other live ones, and was the 197th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Osteoarthritis with a site in Canada, or all of them as a file.
02

Study summary

This study involves the use of sound waves to block pain signals caused by osteoarthritis of the knee. The sound waves are tightly focused on a specific area of the nerve. The sound waves cause a break in the nerve which carries pain signals. Sound waves transmit through the skin so there is no need for needles. The procedure takes approximately one hour. The device has been approved in Health Canada and Europe for the treatment of lower back pain. This study is to evaluate the use of the same device for people in Canada who have knee pain related to osteoarthritis.

Read the detailed description

The research staff will provide a detailed description of the procedure to the study participant live, allowing time for the participant to ask questions. Once the participant agrees to be in the study, an informed consent form will be signed.

Throughout the study, the research team will closely follow the participants health as it is related to their knee. The participant will have a physical exam of their knee and a pressure algometry test at each onsite visit. They will also rate their pain level on a numerical scale, provide a history of medications taken, and complete several quality of life questionnaires.

The participant will be asked to take their usual pain medication prior to the procedure. The study doctor may also provide additional medication depending on the study participants situation.

The study procedure will last approximately 1 hour. The procedure will take place using a standard X-ray device which allows the study doctor to see the structure of the knee and allow for location of the nerve causing knee pain.

The study device will use ultrasound waves to cause damage to the nerve of the knee where the pain is generated. The goal is to interrupt the pain signal pathway. The ultrasound waves go through the skin so no needles or incisions are needed.

It is unknown how much pain relief the participant will feel or how long it will last. The purpose of the study is to evaluate ten people who have the study procedure. If the study results are good, the manufacturer of the device plans to open up a larger study to involve more study participants.

For participants who have access and a MRI is not contraindicated, a follow-up MRI exam will be performed from day 5 to 7 of the participant's knee.

03

Conditions studied

  • Osteoarthritis (OA) of the Knee
  • Knee Pain Arthritis
  • Chronic Knee Pain

Browse trials for

Keywords

  • osteoarthritis
  • knee pain
  • focused ultrasound
  • nerve ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Moderate to severe, predominantly medial chronic knee pain
  2. Age adult >18 years old
  3. WOMAC Score of 30 or higher
  4. NRS>6 with ambulation
  5. Radiological confirmation of knee osteoarthritis (Kellgren-Lawrence Scale: 2-4)
  6. Participants in whom the measured skin to bone depth is 2-6 cm using imaging ultrasound and ultrasound gel pad in the upper medial and lower medial joint capsule targets.

Exclusion criteria

Exclusion Criteria:

  1. Individuals meeting any of the following criteria are not eligible for participation in this study:
  2. Individuals after any surgery associated with altered integrity of bone structure
  3. Individuals with severe pain in the second knee
  4. Individuals unable to understand and complete the research questionnaires in the official language
  5. Individuals presenting with any severe medical condition preventing the participant from safely and effectively being treated in the study or reporting study outcomes, per PI decision
  6. Individuals with extensive scarring of the skin and tissue overlying the treatment area
  7. Individuals enrolled in or planned to be enrolled in another clinical trial during the duration of this research project
  8. Individuals with active inflammatory (e.g., rheumatoid) arthritis
  9. Individuals with concomitant mental health disorders, excluding compensated mood disorders
  10. Individuals with altered perception and processing of pain: Average NRS > 9, PCS>30, SSS-8 > 11, CSI>40 [46], [47], [48]
  11. Individuals with a first-degree family member already enrolled in this study
  12. Individuals who are scheduled for any interventional/surgical procedure within 3 months from the screening date, excluding trivial surgeries (e.g., cataract, skin tumors)
  13. Inability to attend follow-up visits and physiotherapy due to travel distance or other restrictions
  14. Symptomatic multifocal nociplastic chronic pain (e.g., fibromyalgia, generalized osteoarthritis) or any other chronic pain condition that could influence symptoms.
  15. Participants who have undergone radiofrequency ablation of the genicular nerves in the planned treatment limb within the preceding 6 months.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Thermal ablation with Neurolyser XR

    Ablation of sensory nerves in the knee joint

    Device: Neurotomy of the medial sensory articular branches

Interventions

  • DeviceNeurotomy of the medial sensory articular branches

    Non-invasive thermal ablation of the medial sensory articular branches of the knee joint

    Also known as: Nerve ablation, genicular nerve ablation

06

What researchers measure

Primary outcomes

  1. A positive clinical outcome will be measured by a 2-point reduction in the Numerical Rating Score (NRS)

    The NRS score is a 10 point scale, 0 to 10, with 0 meaning "no pain" and 10 meaning "worst possible pain"; the NRS score will be measured at baseline and all follow-up intervals - 2 days, 7 days, 1 month, 3 months, and 6 months..

    Time frame: Baseline score will be compared to post procedure intervals at 2 days, 7 days, 1 month, 3 months, and 6 months.

  2. Safety will be measured by the incidence and severity of treatment-related adverse events.

    Adverse events will be evaluated throughout the study.

    Time frame: Adverse events will be evaluated at baseline and post procedure - 2 days, 7 days, 1 month, 3 months, and 6 months.

Secondary outcomes

  1. Lesion size and location

    Lesion size and location as shown in MRI images post treatment as available

    Time frame: Participants will have an MRI 5-7 days post treatment when feasible and not contraindicated

  2. Procedure time (in minutes)

    Procedure time will be documented from start to finish

    Time frame: The time of the procedure will be documented in minutes.

  3. Radiation exposure (in seconds)

    The procedure is completed using fluroscopy. The fluroscopy time is calculated by the C-Arm. This number will be documented.

    Time frame: The fluoroscopy time will be calculated and documented during the procedure.

  4. Periprocedural analgesic/sedative requirement

    Analgesic/sedatives used during the procedure will be documented.

    Time frame: During the procedure, analgesic/sedative use will be documented.

  5. Change in Pain Pressure Threshold (PPT) as measured on the tibial plateau.

    A pressure algometry device will be used to measure the pain pressure threshold throughout the study.

    Time frame: The PPT will be evaluated and documented at baseline and at follow-up intervals - 2 days, 7 days, 1 month, 3 months, and 6 months

  6. Change in score Patient Global Impression of Change (PGIC)

    The PGIC questionnaire will be given to participants during their onsite follow up visits.

    Time frame: PGIC questionnaires will be provided to participants 1 month, 3 months, and 6 months post procedure.

07

Study locations

1 of 1 sites recruiting
  • Unika Medical Centre
    North York, Ontario M3J 0H1, Canada
    Recruiting
    • Melissa Diep, Research Coordinator · Contactassistant@unikamed.com · 647-740-0160
    • Michael Gofeld, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — This is a pilot study. If results are positive, we plan to organize a larger pivotal study.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

Of 135 industry-sponsored interventional studies with no phase under Osteoarthritis, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 81. This study's planned 3 months is below that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2025
First posted
Sep 17, 2025
StartActual
Sep 9, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 30, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07178951
Lead sponsor
FUSMobile Inc.
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Sep 9, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Melissa Diep Research Coordinator
Contact
assistant@unikamed.com
647-740-0160 Canada

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion